1-5 of 5
Ching Ching Leow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Wei Yang, Colleen Burns, Kevin Lindquist, Julie Dobkin, Hee Rae Shin, Cindy Nguyen, Xiaodong Huang, Whitney Helms, Nicholas Arce, Yvonne Mak, Audrey Au, Abraham Abouzeid, Marta Witek, Ching Ching Leow, Xueqian Gong, Mohan Srinivasan, Joshua I. Park, Kyla Driscoll, Andrew Hass, Rikke Holmgaard, Omar Duramad, Kristin Bedard
Journal: Blood
Blood (2024) 144 (Supplement 1): 2785.
https://doi.org/10.1182/blood-2024-200316
Published: 2024
Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey Roeker, John M. Burke, Christine I Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, Shuhua Yi, Ru Feng, Vu Minh Hua, Jadwiga Holodja, Wojciech Jurczak, Matthias Ritgen, Lu-Gui Qiu, Francesc Bosch, Catherine C. Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Ying (Denise) Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M Barr
Journal: Blood
Blood (2024) 144 (Supplement 1): 886.
https://doi.org/10.1182/blood-2024-198147
Published: 2024
Journal Articles

BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Wojciech Jurczak, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda, Pier Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 3732.
https://doi.org/10.1182/blood-2021-145938
Published: 2021
Journal Articles

BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Jeff P. Sharman, Wojciech Jurczak, Catherine C. Coombs, Marisa Hill, Denise Wang, Nora C. Ku, Ananya Guntur, Safi Shahda, Ching Ching Leow, Paolo Ghia, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 3736.
https://doi.org/10.1182/blood-2021-145926
Published: 2021
Journal Articles

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Anthony R. Mato, William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu, Safi Shahda, Ching Ching Leow, Constantine S. Tam, Jennifer A. Woyach, Toby A. Eyre
Journal: Blood
Blood (2021) 138 (Supplement 1): 3742.
https://doi.org/10.1182/blood-2021-145936
Published: 2021